Korea's Genexine Licenses China Rights for EPO Drug to Fosun Pharma

Genexine Inc. of Korea out-licensed China rights for a novel long-acting EPO drug to a subsidiary of Shanghai Fosun Pharma in a $44.5 million deal. GX-E2 is a Fc-engineered (hyFc) long-acting EPO aimed at anemia caused by chronic kidney disease or chemotherapy. Genexine, which is currently conducting a Phase II trial of the candidate in Korea, will also receive royalties on any China sales of GX-E2. More details.... Stock Symbols: (KOSDAQ: 095700) (SHA: 600196; HK: 02196) Share this with colleagues: // //